MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Начало・Списък с акции・InflaRx NV

InflaRx NV

Затворен

0.99 -2.94

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.94

Максимум

1.05

Ключови измерители
By Trading Economics
Приходи	12M -5.1M
Продажби	-124K -423
EPS	-0.08
Марж на печалбата	1,208,456.738
Служители	74
EBITDA	12M -5M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+630.48% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-11M 70M
Предишно отваряне	3.93
Предишно затваряне	0.99

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

1.05 / 1.24 Подкрепа & съпротива

InflaRx NV Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.04.2025 г., 22:38 ч. UTC

Горещи акции

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

4.04.2025 г., 21:53 ч. UTC

Пазарно говорене

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4.04.2025 г., 21:44 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4.04.2025 г., 21:00 ч. UTC

Топ новини

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4.04.2025 г., 20:52 ч. UTC

Пазарно говорене

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4.04.2025 г., 20:52 ч. UTC

Топ новини

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.04.2025 г., 20:48 ч. UTC

Топ новини

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4.04.2025 г., 20:45 ч. UTC

Топ новини

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4.04.2025 г., 20:32 ч. UTC

Топ новини

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4.04.2025 г., 20:21 ч. UTC

Топ новини

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4.04.2025 г., 20:00 ч. UTC

Топ новини

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4.04.2025 г., 19:51 ч. UTC

Пазарно говорене

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4.04.2025 г., 19:37 ч. UTC

Топ новини

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4.04.2025 г., 19:32 ч. UTC

Пазарно говорене

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4.04.2025 г., 19:28 ч. UTC

Топ новини

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4.04.2025 г., 19:15 ч. UTC

Пазарно говорене

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4.04.2025 г., 19:12 ч. UTC

Топ новини

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4.04.2025 г., 19:11 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4.04.2025 г., 19:09 ч. UTC

Пазарно говорене

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4.04.2025 г., 19:09 ч. UTC

Топ новини

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4.04.2025 г., 19:00 ч. UTC

Пазарно говорене

Fed Has Limited Options to Counter Tariffs -- Market Talk

4.04.2025 г., 18:53 ч. UTC

Пазарно говорене

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4.04.2025 г., 18:51 ч. UTC

Пазарно говорене

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

4.04.2025 г., 18:44 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

4.04.2025 г., 18:44 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.04.2025 г., 18:44 ч. UTC

Пазарно говорене

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

4.04.2025 г., 18:43 ч. UTC

Придобивния, сливания и поглъщания

Trump Extends Deadline for TikTok Ban Another 75 Days. ByteDance Says 'An Agreement Has Not Been Executed.' -- Barrons.com

4.04.2025 г., 18:43 ч. UTC

Придобивния, сливания и поглъщания

Trump Extends TikTok Ban Deadline A Second Time As Deal Chatter Swirls -- IBD

4.04.2025 г., 18:39 ч. UTC

Пазарно говорене

Protectionism is Back, And Recession Could Follow, Morgan Stanley Says -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

InflaRx NV Прогноза

Ценова цел

By TipRanks

630.48% нагоре

12-месечна прогноза

Среден 7.67 USD 630.48%

Висок 10 USD

Нисък 5 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за InflaRx NV през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на InflaRx NV през последните 3 месеца.

Техническа оценка

By Trading Central

1.05 / 1.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно InflaRx NV

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.